AACP
KURA icon

Advantage Alpha Capital Partners’s Kura Oncology KURA Stock Holding History

Advantage Alpha Capital Partners’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-42,958
Closed -$380K – 67
2025
Q3 		$380K Buy
+42,958
New +$306K 0.11% 115

Other funds holding KURA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Advantage Alpha Capital Partners's KURA Position: Q4 2025 in Review

Advantage Alpha Capital Partners sold out of Kura Oncology (KURA) in Q4 2025, closing a stake of 42,958 shares — an estimated $380K sold.

Advantage Alpha Capital Partners first reported a position in KURA in Q3 2025 and held it in 1 quarter. The position peaked at $380K in Q3 2025. 215 funds tracked by Wall St. Rank hold KURA as of Q4 2025.

  • Advantage Alpha Capital Partners reported no remaining Kura Oncology position as of Q4 2025 after selling out during the quarter.
  • Advantage Alpha Capital Partners sold 42,958 Kura Oncology shares in Q4 2025, an estimated $380K.
  • Advantage Alpha Capital Partners first reported a position in Kura Oncology in Q3 2025 and held it in 1 quarter.
  • Advantage Alpha Capital Partners's Kura Oncology position peaked at $380K in Q3 2025.
  • 215 funds tracked by Wall St. Rank held Kura Oncology as of Q4 2025.

Based on Advantage Alpha Capital Partners's 13F filing for Q4 2025.